Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

EXEL 10.15.2024

Full Press ReleaseSEC FilingsOur EXEL Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.12.2025 - Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
  • 01.09.2025 - Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Recent Filings

  • 01.17.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report

ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 15, 2024--Exelixis, Inc.(Nasdaq: EXEL) today announced that in the lawsuitExelixis, Inc.(Exelixis) vs.MSN Laboratories Private Limitedet al. (MSN), Civil Action No. 22-00228 (Consolidated), theU.S. District Court for the District of Delawareruled in Exelixis’ favor, rejecting MSN’s challenge to three Orange Book-listed patents related to cabozantinib, includingU.S.Patents No. 11,091,439 (crystalline salt); 11,091,440 (pharmaceutical compositions); and 11,098,015 (methods of treatment). The District Court’s decision in Exelixis’ favor on the validity of these patents follows an earlier Stipulation entered onJune 21, 2022, that MSN’s proposed generic cabozantinib product (Abbreviated New Drug Application [ANDA] No. 213878) infringes the ’439, ’440, and ’015 patents, which expire onJanuary 15, 2030.

Additionally, the court ruled that Exelixis’ pharmaceutical composition patent (U.S. 11,298,349) is not invalid and not infringed by MSN’s proposed ANDA product.

“We are pleased with the court’s ruling, which upheld the validity of Exelixis’ ‘439, ‘440, ‘015 and ‘349 patents,” saidMichael M. Morrissey, Ph.D., President and Chief Executive Officer,Exelixis. “We remain confident in the strength of the current and emerging cabozantinib patent estate. We will continue to pursue every available legal action to defend our intellectual property rights, which are crucial to safeguarding the scientific innovation that drives our mission to help cancer patients recover stronger and live longer.”

MSN is seeking approval for a product containing a different polymorphic form of cabozantinib (l)-malate than the form contained in Exelixis’ breakthrough CABOMETYX®(cabozantinib) product. To Exelixis’ knowledge, theU.S. Food and Drug Administration(FDA) has not yet granted tentative approval of that potential product. If the FDA ultimately approves MSN’s ANDA, given today’s decision, the earliest that MSN may be permitted to commercially launch its proposed generic product in theU.S.isJanuary 15, 2030, subject to any appeals or additional regulatory exclusivity.

AboutExelixis

Exelixisis a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX®(cabozantinib).Exelixisis driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visitwww.exelixis.com, follow@ExelixisIncon X (Twitter), likeExelixis, Inc.on Facebook and followExelixison LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to: Exelixis’ confidence in the strength of the cabozantinib patent estate and plans to pursue every available legal action to defend its intellectual property rights; the potential timing for MSN to commercially launch its proposed generic product in theU.S.; Exelixis’ and Exelixis’ scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Exelixis’ ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of CABOMETYX; the degree of market acceptance of CABOMETYX in the indications for which it is approved and in the territories where it is approved, and Exelixis’ and its partners’ ability to obtain or maintain coverage and reimbursement for this product; the effectiveness of CABOMETYX in comparison to competing products; Exelixis’ and its partners’ ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so; Exelixis’ and its partners’ continuing compliance with applicable legal and regulatory requirements; Exelixis’ dependence on third-party vendors for the development, manufacture and supply of cabozantinib; changes in economic and business conditions; and other factors detailed from time to time under the caption “Risk Factors” in Exelixis’ most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis’ other future filings with theSecurities and Exchange Commission. All forward-looking statements in this press release are based on information available toExelixisas of the date of this press release, andExelixisundertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

Exelixis, theExelixislogo and CABOMETYX are registeredU.S.trademarks ofExelixis.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241015378225/en/

Investors Contact:Susan HubbardEVP, Public Affairs andInvestor RelationsExelixis, Inc.(650) 837-8194shubbard@exelixis.comMedia Contact:Claire McConnaugheySenior Director, Public AffairsExelixis, Inc.(650) 837-7052cmcconn@exelixis.com

Source:Exelixis, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com